A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Phase 1
150
about 1.7 years
18+
17 sites in CA, CO, DC +11
About this study
This trial is testing a treatment called NVL-330 for people with advanced or metastatic lung cancer that has changes to the HER2 gene. The goal is to see if it's safe and effective, determine the best dose, and evaluate its potential to fight the cancer.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take NVL-330
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Incidence and severity of Treatment Emergent Adverse Events (TEAEs), Maximum Tolerated Dose (MTD), Recommended Phase 2 Dose (RP2D)
Secondary: Duration of Response (DOR), Effect of Food on Maximum Plasma Concentration (Cmax) of NVL-330, Effect of Food on Time of Maximum Concentration (Tmax) of NVL-330, Half-life (t1/2) of NVL-330, Intracranial Duration of Response (IC-DOR), Intracranial Objective Response Rate (IC-ORR), Maximum plasma concentration (Cmax) of NVL-330, Maximum plasma concentration (Cmax- dose normalized) of NVL-330
Oncology